Not willy-nilly, not just like, Hey, let's just give GLP one to everyone
The Bridge adds a new layer of routing complexity on top of that baseline
Cost should never be the primary factor in choosing a treatment approach, but accessibility matters
For patients who want the most comprehensive peptide education available, SeekPeptides offers evidence-based guides, proven protocols, and a community of thousands who have navigated the full spectrum of GLP-1 treatment decisions
Plateau responders: the strongest candidates If semaglutide worked initially but stalled after 4 to 6 months, you are the ideal candidate for switching
Tuesdays approval is backed by data from a Phase III trial comprising around 400 patients with a history of bipolar I disorder who are currently suffering from a manic episode